Poxel announces the signing of an agreement with IPF Partners to restructure its existing debt and the establishment of an equity financing line with Iris Capital Investment for a maximum amount of six million euros.
Based on these two agreements, the biopharmaceutical company specializing in NASH and rare metabolic diseases estimates that its resources will be sufficient to finance its operations and its investment needs at least until February 2023.
‘We are going to take an important step this quarter with the first results of the phase II DESTINY-1 study for PXL065 in NASH’, explained its managing director Thomas Kuhn on this occasion.
Copyright (c) 2022 CercleFinance.com. All rights reserved.